Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.30 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7893868 | 0.80 | KDM4E (0.50) | KDM4EMAPTALDH1A1RAB9APIK3CG | |
| SCHEMBL14781571 | 0.78 | PIK3CG (0.36) | PIK3CG | |
| SCHEMBL13050446 | 0.78 | GRN (0.35) | KDM4EGAAMAPTALDH1A1LMNA | |
| SCHEMBL7887500 | 0.77 | KDM4E (0.35) | KDM4EMAPTALDH1A1RAB9APIK3CG | |
| SCHEMBL10282570 | 0.77 | L3MBTL1 (0.41) | KDM4EMAPTALDH1A1RAB9APIK3CG | |
| SCHEMBL7886825 | 0.77 | KDM4E (0.35) | KDM4EMAPTALDH1A1RAB9APIK3CG | |
| SCHEMBL13080156 | 0.77 | SYK (0.34) | — | |
| SCHEMBL14902322 | 0.74 | SYK (0.35) | KDM4EMAPTALDH1A1RAB9APIK3CG | |
| SCHEMBL19185271 | 0.74 | SYK (0.35) | KDM4EMAPTALDH1A1PIK3CGL3MBTL1 | |
| SCHEMBL7894717 | 0.74 | SYK (0.39) | KDM4EGAAMAPTPIK3CGL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3020716-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | Forum Pharmaceuticals Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20150322069-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | FMR LLC | 2015-11-12 | — | — | US | disclosed |
| US-8946222-B2 | Phenoxymethyl heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2015-02-03 | — | — | US | disclosed |
| WO-2014131739-A2 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-04 | — | — | WO | disclosed |
| WO-2013135612-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-19 | — | — | WO | disclosed |
| US-20130143888-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | ENVIVO PHAMACEUTICALS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| EP-2427454-B1 | Phenoxymethyl heterocyclic compounds | ENVIVO PHARMACEUTICALS INC (US) | 2013-03-20 | — | — | EP | disclosed |
| WO-2010128995-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322069-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | PDE3A, PDE2A, PDE5A | KDM4E 559/4885GAA 93/4885MAPT 1299/4885 |
| US-20130143888-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | PDE3A, PDE2A, PDE5A | KDM4E 559/4885GAA 93/4885MAPT 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.